Use of PAF antagonists - for diagnosis and treatment of cholesterasis and Lecithin Cholesterol Acyl Transferase deficiency

摘要

The following are claimed: (A) use of PAF-antagonists for (i) treatment or prophylaxis of diseases associated with an elevated level of lipoprotein X in blood, (ii) treatment of cholestasis and lecithin-cholesterol -acyl-transferase (LCAT) deficiency, and (iii) differential diagnosis between cholestatic and non-cholestatic liver disorders. (B) Determination of PAF-acetylthydrolase activity in serum is used for (i) diagnosis of cholestases and LCAT deficiency disorders, (ii) monitoring the course of a cholestatic disease, and (iii) assessing the success of therapy of cholestatic diseases with PAF-antagonists. (C) Use of PAF antagonists in prepn. of medicaments for (i) treatment of prophylaxis of diseases associated with elevated lipoprotein-X levels in blood, and (ii) treatment of cholestasis or LCAT deficiency disease. USE/ADVANTAGE - Presence of lipoprotein X is specific for existence of an intra- or extra-hepatic cholestasis or LCAT-deficiency disease. In these cases the level of PAF-acetyl-hydrolase is also increased. By using a PAF-antagonists to block PAF-receptors the activity of lipoprotein X (which acts at those receptors) is stopped, the elevated level of the lipoprotein X is removed and the disease may be treated. Admin. is topical, oral, parenteral, transdermal or by inhalation in doses of 1-50 (esp. 3-20) mg/dose (p.o.) or 0.01-50 (esp.0.1-10) mg/dose (i.v. or i.m.)